Both Capricor Therapeutics Inc. (NASDAQ:CAPR) and argenx SE (NASDAQ:ARGX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics Inc.	1.67M	12.89	15.19M	-0.11	0.00
argenx SE	N/A	0.00	N/A	-1.73	0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows Capricor Therapeutics Inc. and argenx SE’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics Inc.	-909.58%	3.9%	2.6%
argenx SE	0.00%	0%	0%

Analyst Ratings

Capricor Therapeutics Inc. and argenx SE Recommendations and Ratings are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Capricor Therapeutics Inc.	0	0	1	3.00
argenx SE	0	0	2	3.00

The consensus target price of Capricor Therapeutics Inc. is $3.5, with potential upside of 446.88%. Competitively the consensus target price of argenx SE is $150.5, which is potential 16.75% upside. The data from earlier shows that analysts belief suggest that Capricor Therapeutics Inc. seems more appealing than argenx SE.

Institutional & Insider Ownership

Capricor Therapeutics Inc. and argenx SE has shares owned by institutional investors as follows: 5.4% and 55.31%. Capricor Therapeutics Inc.’s share owned by insiders are 35.68%.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Capricor Therapeutics Inc.	11.49%	-4.62%	-40.85%	-59.58%	-71.97%	18.29%
argenx SE	2.01%	24.83%	40.83%	43.87%	61.6%	37.88%

For the past year Capricor Therapeutics Inc.’s stock price has smaller growth than argenx SE.

Summary

Capricor Therapeutics Inc. beats on 7 of the 10 factors argenx SE.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The companyÂ’s development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.